Buscar
VolitionRX Ltd
VNRXAñadir a la lista de seguimiento
0.847USD
-0.033-3.74%
Cierre 07-28 16:00（ET）Cotizaciones retrasadas 15 min
335.90KCap. mercado
PérdidaP/E TTM
Más Datos de VolitionRX Ltd Compañía
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Información de VolitionRX Ltd
Símbolo de cotizaciónVNRX
Nombre de la empresaVolitionRX Ltd
Fecha de salida a bolsaFeb 06, 2015
Director ejecutivoButera (Salvatore Thomas)
Número de empleados85
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 06
Dirección1489 West Warm Springs Road
CiudadHENDERSON
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal89014
Teléfono17024251561
Sitio Webhttps://volition.com/
Símbolo de cotizaciónVNRX
Fecha de salida a bolsaFeb 06, 2015
Director ejecutivoButera (Salvatore Thomas)
Ejecutivos de VolitionRX Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
18.19K
-3.54%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
16.56K
-2.28%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
13.70K
-2.65%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
12.24K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
170.16K
--
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.36K
--
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.97K
+31.59%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
31.19K
-0.85%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
21.20K
+40.80%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
20.68K
+8.40%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de VolitionRX Ltd?
Los cinco principales accionistas de VolitionRX Ltd son: Mr. Guy Archibald Innes
¿Cuántas instituciones poseen acciones de VolitionRX Ltd (VNRX)?
A fecha de 2026Q1, 66 instituciones poseen acciones de VolitionRX Ltd, con un valor de mercado combinado de aproximadamente 1.13M, lo que representa el 13.93% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -209799.00.